Phibro Animal Health appoints Joyce J. Lee as independent Class II director
Phibro Animal Health's Board appointed Joyce J. Lee as a Class II independent director, effective January 21, 2025. The appointment fills a current vacancy and raises Board membership to nine directors, six of them independent. The filing describes a board seat change and does not report any financial results or guidance.
Key points
- Joyce J. Lee appointed Class II director effective January 21, 2025; expected to stand for election at the 2027 Annual Meeting
- Board increases to nine directors, six of whom are independent
- Lee was most recently President of Cobb Vantress LLC and previously held executive roles at Elanco, Bayer Animal Health, and Zoetis
- Lee receives the same non-employee director compensation and the standard director indemnification agreement
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 23, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.